Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13944619 | 0.88 | LMNA (0.81) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| Proxyphylline SCHEMBL35569 | 0.87 | LMNA (1.00) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| (S)-Proxyphylline SCHEMBL35570 | 0.87 | LMNA (1.00) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL11601258 | 0.86 | LMNA (0.78) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL11830512 | 0.86 | LMNA (0.77) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL17486883 | 0.85 | LMNA (0.76) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL10653583 | 0.85 | SMN1; SMN2 (0.71) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL10859640 | 0.84 | LMNA (0.80) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| Dyphylline SCHEMBL1816552 | 0.84 | LMNA (1.00) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| Dyphylline SCHEMBL123781 | 0.84 | LMNA (1.00) | LMNASMN1; SMN2POLBADORA2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | LMNA 819/4885SMN1; SMN2 129/4885POLB 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.